Ian H de Boer1, Michael C Sachs2, Michel Chonchol3, Jonathan Himmelfarb2, Andrew N Hoofnagle4, Joachim H Ix5, Robin A Kremsdorf6, Yvonne S Lin7, Rajnish Mehrotra2, Cassianne Robinson-Cohen8, David S Siscovick9, Michael W Steffes10, Kenneth E Thummel7, Russell P Tracy11, Zhican Wang7, Bryan Kestenbaum8. 1. Division of Nephrology, Department of Medicine, Seattle, WA; Kidney Research Institute, Department of Medicine, Seattle, WA; Department of Epidemiology, University of Washington, Seattle, WA. Electronic address: deboer@u.washington.edu. 2. Division of Nephrology, Department of Medicine, Seattle, WA; Kidney Research Institute, Department of Medicine, Seattle, WA. 3. Division of Nephrology, Department of Medicine, University of Colorado, Denver, CO. 4. Kidney Research Institute, Department of Medicine, Seattle, WA; Department of Laboratory Medicine, University of Washington, Seattle, WA. 5. Division of Nephrology, Department of Medicine, University of California, San Diego, San Diego, CA. 6. Kidney Research Institute, Department of Medicine, Seattle, WA; Division of Nephrology, Department of Pediatrics, Seattle Children's Hospital, Seattle, WA. 7. Department of Pharmaceutics, Department of Medicine, University of Washington, Seattle, WA. 8. Division of Nephrology, Department of Medicine, Seattle, WA; Kidney Research Institute, Department of Medicine, Seattle, WA; Department of Epidemiology, University of Washington, Seattle, WA. 9. Department of Epidemiology, University of Washington, Seattle, WA; Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA. 10. Department of Laboratory Medicine, University of Minnesota, Minneapolis, MN. 11. Department of Laboratory Medicine, University of Vermont, Burlington, VT.
Abstract
BACKGROUND: Decreased glomerular filtration rate (GFR) leads to reduced production of 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3 (25[OH]D3). Effects of low GFR on vitamin D catabolism are less well understood. We tested associations of estimated GFR (eGFR) with the circulating concentration of 24,25-dihydroxyvitamin D3 (24,25[OH]2D3), the most abundant product of 25(OH)D3 catabolism, across populations with a wide range of GFRs. STUDY DESIGN: Cross-sectional study. SETTING & PARTICIPANTS: 9,596 participants in 5 cohort studies and clinical trials: the Diabetes Control and Complications Trial (N=1,193), Multi-Ethnic Study of Atherosclerosis (N=6,470), Cardiovascular Health Study (N=932), Seattle Kidney Study (N=289), and Hemodialysis Study (N=712). PREDICTOR: eGFR. OUTCOME: Circulating 24,25(OH)2D3 concentration. MEASUREMENTS: GFR was estimated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration equation. Vitamin D metabolites were measured by mass spectrometry. RESULTS: Circulating 24,25(OH)2D3 concentration was correlated with circulating 25(OH)D3 concentration (Pearson r range, 0.64-0.88). This correlation was weaker with lower eGFRs. Moreover, the increment in 24,25(OH)2D3 concentration associated with higher 25(OH)D3 concentration (slope) was lower with lower eGFRs: 2.06 (95% CI, 2.01-2.10), 1.77 (95% CI, 1.74-1.81), 1.55 (95% CI, 1.48-1.62), 1.17 (95% CI, 1.05-1.29), 0.92 (95% CI, 0.74-1.10), 0.61 (95% CI, 0.22-1.00), and 0.37 (95% CI, 0.35-0.39) ng/mL of 24,25(OH)2D3 per 10 ng/mL of 25(OH)D3 for eGFRs≥90, 60-89, 45-59, 30-44, 15-29, and <15 mL/min/1.73 m2 and end-stage renal disease treated with hemodialysis, respectively. As a result, at a 25(OH)D3 concentration of 20 ng/mL, mean 24,25(OH)2D3 concentrations were 2.92 (95% CI, 2.87-2.96), 2.68 (95% CI, 2.64-2.72), 2.35 (95% CI, 2.26-2.45), 1.92 (95% CI, 1.74-2.10), 1.69 (95% CI, 1.43-1.95), 1.14 (95% CI, 0.62-1.66), and 1.04 (95% CI,1.02-1.07) ng/mL for each category, respectively. This interaction was independent of other relevant clinical characteristics. Race, diabetes, urine albumin excretion, and circulating parathyroid hormone and fibroblast growth factor 23 concentrations more modestly modified the association of 24,25(OH)2D3 with 25(OH)D3. LIMITATIONS: Lack of direct pharmacokinetic measurements of vitamin D catabolism. CONCLUSIONS: Lower eGFR is associated strongly with reduced vitamin D catabolism, as measured by circulating 24,25(OH)2D3 concentration.
BACKGROUND: Decreased glomerular filtration rate (GFR) leads to reduced production of 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3 (25[OH]D3). Effects of low GFR on vitamin D catabolism are less well understood. We tested associations of estimated GFR (eGFR) with the circulating concentration of 24,25-dihydroxyvitamin D3 (24,25[OH]2D3), the most abundant product of 25(OH)D3 catabolism, across populations with a wide range of GFRs. STUDY DESIGN: Cross-sectional study. SETTING & PARTICIPANTS: 9,596 participants in 5 cohort studies and clinical trials: the Diabetes Control and Complications Trial (N=1,193), Multi-Ethnic Study of Atherosclerosis (N=6,470), Cardiovascular Health Study (N=932), Seattle Kidney Study (N=289), and Hemodialysis Study (N=712). PREDICTOR: eGFR. OUTCOME: Circulating 24,25(OH)2D3 concentration. MEASUREMENTS: GFR was estimated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration equation. Vitamin D metabolites were measured by mass spectrometry. RESULTS: Circulating 24,25(OH)2D3 concentration was correlated with circulating 25(OH)D3 concentration (Pearson r range, 0.64-0.88). This correlation was weaker with lower eGFRs. Moreover, the increment in 24,25(OH)2D3 concentration associated with higher 25(OH)D3 concentration (slope) was lower with lower eGFRs: 2.06 (95% CI, 2.01-2.10), 1.77 (95% CI, 1.74-1.81), 1.55 (95% CI, 1.48-1.62), 1.17 (95% CI, 1.05-1.29), 0.92 (95% CI, 0.74-1.10), 0.61 (95% CI, 0.22-1.00), and 0.37 (95% CI, 0.35-0.39) ng/mL of 24,25(OH)2D3 per 10 ng/mL of 25(OH)D3 for eGFRs≥90, 60-89, 45-59, 30-44, 15-29, and <15 mL/min/1.73 m2 and end-stage renal disease treated with hemodialysis, respectively. As a result, at a 25(OH)D3 concentration of 20 ng/mL, mean 24,25(OH)2D3 concentrations were 2.92 (95% CI, 2.87-2.96), 2.68 (95% CI, 2.64-2.72), 2.35 (95% CI, 2.26-2.45), 1.92 (95% CI, 1.74-2.10), 1.69 (95% CI, 1.43-1.95), 1.14 (95% CI, 0.62-1.66), and 1.04 (95% CI,1.02-1.07) ng/mL for each category, respectively. This interaction was independent of other relevant clinical characteristics. Race, diabetes, urine albumin excretion, and circulating parathyroid hormone and fibroblast growth factor 23 concentrations more modestly modified the association of 24,25(OH)2D3 with 25(OH)D3. LIMITATIONS: Lack of direct pharmacokinetic measurements of vitamin D catabolism. CONCLUSIONS: Lower eGFR is associated strongly with reduced vitamin D catabolism, as measured by circulating 24,25(OH)2D3 concentration.
Authors: Jessica Kendrick; Alfred K Cheung; James S Kaufman; Tom Greene; William L Roberts; Gerard Smits; Michel Chonchol Journal: Am J Kidney Dis Date: 2012-05-22 Impact factor: 8.860
Authors: Garabed Eknoyan; Gerald J Beck; Alfred K Cheung; John T Daugirdas; Tom Greene; John W Kusek; Michael Allon; James Bailey; James A Delmez; Thomas A Depner; Johanna T Dwyer; Andrew S Levey; Nathan W Levin; Edgar Milford; Daniel B Ornt; Michael V Rocco; Gerald Schulman; Steve J Schwab; Brendan P Teehan; Robert Toto Journal: N Engl J Med Date: 2002-12-19 Impact factor: 91.245
Authors: Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: Charles Ginsberg; Leila R Zelnick; Geoffrey A Block; Glenn M Chertow; Michel Chonchol; Andrew Hoofnagle; Bryan Kestenbaum; Ian H de Boer Journal: Nephrol Dial Transplant Date: 2020-04-01 Impact factor: 5.992
Authors: Adriana J van Ballegooijen; Eugene P Rhee; Sammy Elmariah; Ian H de Boer; Bryan Kestenbaum Journal: J Am Soc Nephrol Date: 2015-06-05 Impact factor: 10.121
Authors: Adriana J van Ballegooijen; Cassianne Robinson-Cohen; Ronit Katz; Michael Criqui; Matthew Budoff; Dong Li; David Siscovick; Andy Hoofnagle; Steven J Shea; Gregory Burke; Ian H de Boer; Bryan Kestenbaum Journal: Bone Date: 2015-05-11 Impact factor: 4.398
Authors: Anders H Berg; Camille E Powe; Michele K Evans; Julia Wenger; Guillermo Ortiz; Alan B Zonderman; Pirianthini Suntharalingam; Kathryn Lucchesi; Neil R Powe; S Ananth Karumanchi; Ravi I Thadhani Journal: Clin Chem Date: 2015-04-28 Impact factor: 8.327
Authors: Adriana J van Ballegooijen; Leila Zelnick; Andrew N Hoofnagle; Naomi M Hamburg; Cassiane Robinson-Cohen; Prabir Roy-Chaudhury; Alfred K Cheung; Yan-Ting Shiu; Ian H de Boer; Jonathan Himmelfarb; Gerald Beck; Peter B Imrey; John W Kusek; Bryan Kestenbaum Journal: Am J Kidney Dis Date: 2017-03-27 Impact factor: 8.860
Authors: Charles Ginsberg; Ronit Katz; Ian H de Boer; Bryan R Kestenbaum; Michel Chonchol; Michael G Shlipak; Mark J Sarnak; Andrew N Hoofnagle; Dena E Rifkin; Pranav S Garimella; Joachim H Ix Journal: Bone Date: 2017-11-16 Impact factor: 4.398
Authors: Tomasz Beben; Joachim H Ix; Michael G Shlipak; Mark J Sarnak; Linda F Fried; Andrew N Hoofnagle; Michel Chonchol; Bryan R Kestenbaum; Ian H de Boer; Dena E Rifkin Journal: J Am Geriatr Soc Date: 2016-02 Impact factor: 5.562